Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, Open Label, Non-randomised, Non-comparative, Multi-center Study, Evaluating S65487, a Bcl-2 Inhibitor Intravenously Administered, in Patients With Relapsed or Refractory Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia

NCT03755154 is registered in ClinicalTrials.gov with Institut de Recherches Internationales Servier as lead sponsor.

NCT NCT03755154
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03755154 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, Open Label, Non-randomised, Non-comparative, Multi-center Study, Evaluating S65487, a Bcl-2 Inhibitor Intravenously Administered, in Patients With Relapsed or Refractory Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia
Lead sponsor
Institut de Recherches Internationales Servier
Phase
Phase 1
Overall status
Terminated
Start date
July 17, 2019
Completion date
November 6, 2023
Enrollment
60 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory acute myeloid leukemia, relapsed or refractory chronic lymphocytic leukemia, relapsed or refractory multiple myeloma, relapsed or refractory non-hodgkin lymphoma